@YannickBuccella: The newer generation cancer vaccines aren't like the HPV shot (that prevents a virus). These are therapeutic, they trea…
Summary
The article discusses the advancement of therapeutic cancer vaccines using personalized mRNA technology, highlighting recent positive Phase 3 results for melanoma and ongoing trials for other cancers, with potential approvals expected by 2027.
View Cached Full Text
Cached at: 08/22/26, 11:29 AM
The newer generation cancer vaccines aren’t like the HPV shot (that prevents a virus). These are therapeutic, they treat cancer you already have. And 2026 is the year they stopped being sci-fi.
The idea: after surgery, sequence your specific tumor, find the mutations unique to it, and build a custom mRNA vaccine that trains your immune system to hunt any cell carrying them. A wanted poster for your personal cancer. Where we actually are:
Melanoma: just like in immunotherapy 15 years ago the furthest along. The press release of positive Phase 3 made the headlines yesterday, the first ever for a personalized cancer vaccine. Earlier data: ~49% lower risk of recurrence. Heading to regulators.
Pancreatic cancer: arguably the most stunning. In an early trial, patients whose immune systems responded to the vaccine were far more likely to be alive 6 years later, in a cancer where 5-year survival is barely better than 10 %. Now in a larger trial.
Kidney, lung, bladder, brain: all in trials, mostly early phase. The honest caveats: these work best after surgery to stop recurrence, not to melt large tumors. They’re personalized, so they might cost $100–300k and take weeks to build per patient. And most are still early-phase. First approvals at best 2027.
But the direction is unmistakable. The mRNA platform some parts of the internet spent years calling poison - because they got fooled by bad actors making money on their lies - is turning into the most personalized cancer medicine ever made.
These are the main trials currently running:
Similar Articles
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.
@WSJ: An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validati…
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.
Moderna’s new cancer vaccine (mRNA-4157) is basically an AWS cloud pipeline that "compiles" a custom drug for your specific tumor.
Moderna and Merck's mRNA-4157 vaccine uses a cloud-based AI pipeline to create personalized cancer treatments, reducing recurrence risk by 49%. The FDA treats the AI software as part of the drug, marking a significant integration of technology in oncology.
@EricTopol: The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the mo…
Eric Topol highlights the remarkable progress in cancer immunotherapy, with vaccines achieving cures or remissions in refractory cancers like pancreatic, melanoma, glioblastoma, renal, and triple-negative breast cancer, and directs readers to his Ground Truths newsletter for more.
Moderna stock, $MRNA , surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.